Merck and Isomorphic Labs have entered a research collaboration to discover small-molecule drug candidates against a cancer target. The agreement pairs Isomorphic Labs’ artificial intelligence-based drug design system with Merck’s proprietary data and drug discovery operations.
Isomorphic Labs will use its drug design engine, known as IsoDDE, to make computer-based predictions and deliver molecular designs for the oncology program. Merck will supply selected proprietary datasets for use in the design system and will be responsible for preclinical and clinical development of candidates that emerge from the collaboration. Merck will also handle manufacturing and commercialization of any resulting products.
Under the agreement, Merck will make an upfront payment to Isomorphic Labs. Isomorphic Labs is also eligible for payments tied to specified research, development, regulatory and commercial milestones, along with tiered royalties on net sales. It has the option to share development costs in exchange for higher royalties.
George Addona, who heads discovery, preclinical development and translational medicine at Merck Research Laboratories, said the approach relies on close coordination between laboratory research and computational modeling. Isomorphic Labs Chief Research Officer Sarah Skerratt said the company will use both the generative and predictive capabilities of its design system in the program.
Founded in 2021, Isomorphic Labs develops drug candidates through partnerships and its own research programs. The company is headquartered in London and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!